[Medical treatment of metastatic renal cell carcinoma after the approval and market entry of multitargeted tyrosine kinase inhibitors in Germany]. [electronic resource]
Producer: 20090611Description: 31-6 p. digitalISSN:- 1438-8820
- Aged
- Aged, 80 and over
- Angiogenesis Inhibitors -- administration & dosage
- Antineoplastic Agents -- administration & dosage
- Benzenesulfonates -- administration & dosage
- Carcinoma, Renal Cell -- drug therapy
- Clinical Trials, Phase III as Topic
- Cohort Studies
- Data Interpretation, Statistical
- Female
- Germany
- Humans
- Indoles -- administration & dosage
- Kidney Neoplasms -- drug therapy
- Male
- Medical Oncology
- Middle Aged
- Neoplasm Metastasis
- Niacinamide -- analogs & derivatives
- Phenylurea Compounds
- Protein Kinase Inhibitors -- administration & dosage
- Protein-Tyrosine Kinases -- antagonists & inhibitors
- Pyridines -- administration & dosage
- Pyrroles -- administration & dosage
- Sorafenib
- Sunitinib
- Surveys and Questionnaires
- Time Factors
- Urology
No physical items for this record
Publication Type: Comparative Study; Evaluation Study; Journal Article
There are no comments on this title.
Log in to your account to post a comment.